Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

Company Overview - Beam Therapeutics Inc. (BEAM) shares have increased by approximately 5.7% over the past month, which is underperforming compared to the S&P 500 [1] - The most recent earnings report is essential for understanding the key drivers affecting the stock [1] Earnings Estimates - Estimates for Beam Therapeutics have remained flat over the past month, indicating no significant changes in expectations [2] VGM Scores - Beam Therapeutics has a poor Growth Score of F and a Momentum Score of C, while its Value Score is also rated F, placing it in the lowest quintile for this investment strategy [3] - The overall aggregate VGM Score for Beam Therapeutics is F, which is a critical score for investors not focused on a single strategy [3] Outlook - Beam Therapeutics holds a Zacks Rank of 3 (Hold), suggesting an expectation of an in-line return from the stock in the upcoming months [4] Industry Comparison - Beam Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where Bristol Myers Squibb (BMY) has seen a 0.7% increase in shares over the past month [5] - Bristol Myers reported revenues of $11.2 billion for the last quarter, reflecting a year-over-year decline of 5.6%, with an EPS of $1.80 compared to -$4.40 a year ago [5] - For the current quarter, Bristol Myers is expected to post earnings of $1.67 per share, representing a year-over-year change of -19.3% [6] - The Zacks Consensus Estimate for Bristol Myers has changed by +0.1% over the last 30 days, maintaining a Zacks Rank of 3 (Hold) and a VGM Score of A [6]